Clinical trials: Hemostatic Disorders
Relapsed or Refractory Multiple Myeloma
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to compare the safety and efficacy of QLS32015 with Pd/Sd for the treatment of relapsed or refractory multiple myeloma.
- Trial name
- NCT07138209
- Testing
- QLS32015, Pomalidomide, Selinexor
- Where
- China
- Volunteers
- 228 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Waldenstrom's Macroglobulinemia
Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)
In this study, we are trying to find out if the combination of these two drugs is effective in treating Waldenstrom's macroglobulinemia (WM).
- Trial name
- NCT00422799
- Testing
- Bortezomib, Rituximab
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Dana-Farber Cancer Institute
Hip Fractures, Anticoagulants and Bleeding Disorders
Caudal Block & Hip Fracture Surgery in Anticoagulated Patient
Hip fractures are common in elderly patients, and require surgery. Many elderly patients take anticoagulants for vasculopathy treatment.
- Trial name
- NCT05946863
- Where
- Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Salem Anaesthesia Pain Clinic
Multiple Myeloma
Genomic-Based Diagnosis, Classification and Targeted Treatment of Multiple Myeloma
Multiple myeloma is an incurable bone marrow cancer characterized by an abnormal expansion of plasma cells that secretes monoclonal immunoglobulin.
- Trial name
- NCT01619358
- Where
- Singapore
- Volunteers
- 150 people
- Sponsor
- National University Hospital, Singapore
Multiple Myeloma Refractory, Relapsed Multiple Myeloma
Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager
Bispecific antibody therapies targeting BCMA (B-cell maturation antigen) represent a novel therapeutic approach for patients with multiple myeloma.
- Trial name
- CHUQUL_HO001 (NCT07094048)
- Testing
- Target trough IgG level of 8-10 g/L, Target trough IgG level 4-6 g/L, No history of recurrent or severe infections and total IgG level higher or equal at 4 g/L
- Where
- 2 sites in Canada
- Volunteers
- 80 people
- Sponsor
- CHU de Quebec-Universite Laval
Refractory Multiple Myeloma, Stage II Multiple Myeloma
Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma
This phase I trial is studying the side effects and best dose of temsirolimus when given together with lenalidomide in treating patients with previously treated multiple myeloma.
- Conditions
- Refractory Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT00398515
- Testing
- lenalidomide, temsirolimus, pharmacological study
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma, Heart Disease Risk Factors
MM-CARE: Cardiovascular Risk Assessment in Adults With Multiple Myeloma
People with multiple myeloma may have health conditions or receive treatments that increase their risk of heart and blood-vessel problems.
- Trial name
- MM-CARE (NCT07783607)
- Testing
- Oncology-Embedded Cardiovascular Risk Assessment Pathway, Primary Care Provider-Directed Cardiovascular Risk Assessment Pathway
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Vermont Medical Center
Relapsed/Refractory Multiple Myeloma
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
This trial is a Phase 1b/2, open-label, multicenter study of AZD0120, a CD19/BCMA dual CAR T-cell therapy, in adult subjects with relapsed/refractory multiple myeloma.
- Trial name
- DURGA-1 (NCT05850234)
- Testing
- AZD0120
- Where
- 36 sites in United States
- Volunteers
- 232 people
- Sponsor
- AstraZeneca
Non-Hodgkin's Lymphoma, Multiple
Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma
This study uses a drug called dasatinib to produce an anti-cancer effect called large granular lymphocyte cellular expansion. Large granular lymphocytes are blood cells known as natural killer cells that remove cancer cells.
- Conditions
- Non-Hodgkin's Lymphoma, Multiple, Mycosis Fungoides, Hodgkin's Lymphoma
- Trial name
- NCT01609816
- Testing
- Dasatinib
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Multiple Myeloma
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of…
- Trial name
- iMMagine-3 (NCT06413498)
- Testing
- Anitocabtagene Autoleucel, Cyclophosphamide, Fludarabine
- Where
- 117 sites in United States, Australia and 13 more
- Volunteers
- 452 people
- Sponsor
- Kite, A Gilead Company
Chronic Myeloproliferative Disorders, Leukemia
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
RATIONALE: Antiemetic drugs, such as ondansetron, may help to reduce or prevent nausea and vomiting in patients with advanced cancer.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00006348
- Testing
- ondansetron
- Where
- 12 sites in United States
- Volunteers
- 100 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Multiple Myeloma and Plasma Cell Neoplasm
Combination Chemotherapy in Treating Patients With Stage II or Stage III Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective for multiple myeloma.
- Trial name
- NCT00006232
- Testing
- dexamethasone, doxorubicin hydrochloride, idarubicin
- Where
- 12 sites in United Kingdom
- Volunteers
- 200 people
- Sponsor
- West of Scotland Lymphoma Group
Multiple Myeloma
A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma
The purpose of Phase 1b of the study is to determine the maximum tolerated dose (MTD) of oprozomib in combination with melphalan and prednisone (OMP).
- Trial name
- NCT02072863
- Testing
- Oprozomib, Melphalan, Prednisone
- Where
- 8 sites in Greece, Italy and 1 more
- Volunteers
- 9 people
- Sponsor
- Amgen
Hematologic Disease, Hemophilia A
BAY14-2222 Prophylaxis and Joint Function Improvement (Adults)
The purpose of the study is to evaluate the effect of prophylactic treatment on the number of joint bleeds and quality of life in severe hemophilia A subjects compared to on-demand treatment in a one-group two-treatment schedule…
- Trial name
- NCT00586521
- Testing
- Kogenate (BAY14-2222)
- Where
- 11 sites in United States, France and 3 more
- Volunteers
- 20 people
- Sponsor
- Bayer
Relapsed or Refractory Multiple Myeloma
Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet
A Study Evaluating Treatment of Multiple Myeloma with Carfilzomib in Combination with Pomalidomide and Dexamethasone
- Trial name
- SELECT (NCT04191616)
- Testing
- Carfilzomib, Dexamethasone, Pomalidomide
- Where
- 46 sites in United States, Denmark and 6 more
- Volunteers
- 54 people
- Sponsor
- Amgen
Leukemia, Lymphoma
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00719849
- Testing
- anti-thymocyte globulin, cyclophosphamide, cyclosporine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Fred Hutchinson Cancer Center
Telangiectasia, Hereditary Hemorrhagic
Study of Histological Samples From Patients With Hereditary Haemorrhagic Telangiectasia
In this study the investigators will obtain histological samples from people with hereditary haemorrhagic telangiectasia (HHT, also known as Osler-Weber-Rendu Syndrome).
- Trial name
- NCT00733655
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- Imperial College London
Coronavirus Disease 2019
COVID-19 Associated Lymphopenia Pathogenesis Study in Blood
Background: COVID-19 is an acute respiratory syndrome. One symptom of COVID-19 is a reduction in the number of cells called lymphocytes in the blood. Lymphocytes are a type of white blood cell that fights infections.
- Trial name
- NCT04401436
- Where
- 3 sites in United States
- Volunteers
- 240 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
ISS Stage III Plasma Cell Myeloma, Multiple Myeloma
Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial
This phase II trial test whether combination chemotherapy works to improve blood test results in patients with high-risk multiple myeloma.
- Trial name
- NCT05497804
- Testing
- Bone Marrow Aspiration and Biopsy, Carfilzomib, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- Mayo Clinic
Waldenstrom's Macroglobulinemia
Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's
This is a prospective, multicenter phase II trial designed to determine efficacy and safety of Bortezomib plus Rituximab plus Bendamustine in patients with relapsed/refractory Waldenstrom's Macroglobulinemia.
- Trial name
- FIL_BRB (NCT02371148)
- Testing
- Bortezomib-Rituximab-Bendamustine
- Where
- 23 sites in Italy
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Fondazione Italiana Linfomi - ETS
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.